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The growth rate of tissues including tumors is determined by the difference between cell
replication and cell death. Amongdifferent types ofcell death, apoptosis, a form ofprogrammed
cell death, is of particular importance. Nongenotoxic carcinogens exert their carcinogenic
effects not only via stimulation ofcell replication but also by modulating the incidence ofapop-
tosis. This can be seen at different stages ofcarcinogenesis: a) After initiation in the liver, many
initiated cells may undergo apoptosis and never develop into preneoplastic foci, as suggested
by both biological and mathematical studies. Thus, apoptosis appears to determine the efficien-
cy ofinitiation. b) In the promotion stage, early preneoplastic hepatic foci originate either from
treatment with a genotoxic carcinogen or spontaneously exhibit much higher rates ofcell repli-
cation than normal cells, but nevertheless show little preferential growth. This is due to
enhanced rates ofapoptosis. Some tumor promoters were found to inhibit apoptosis and there-
by accelerate foci growth and carcinogenesis. c) In neoplastic nodules and tumors, apoptosis
has been shown to be an important growth determinant and to be regulated by growth regula-
tory hormones, which thereby may decrease or accelerate tumor growth. Studies on the regula-
tion ofapoptosis revealed that in the liver, transforming growth factorTGF-01 is involved in the
initiation of apoptosis. This was based on three lines of evidence: TGF-fi1 induced apoptosis in
isolated hepatocytes, b) in vivo hepatocytes undergoing apoptosis showed positive immuno-
staining with antibodies against a precursor ofTGF-i1. This staining response was not seen in
normal or necrotic hepatocytes, c) injection ofTGF-I1 into intact animals induced apoptosis in
the liver in vivo.
Introduction
Many seemingly nongenotoxic compounds produce
tumors in rodent liver, some of which (e.g., certain
steroids) have also been associated with tumor forma-
tion in human liver (1,2). A common denominator ofthe
actions of many if not all of these compounds is a
pleiotropic effect on rodent liver consisting of organ
enlargement and hyperplasia associated with function-
al changes such as increases in activities of certain
'Institute of Tumorbiology-Cancer Research, University of
Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
2Department of Radiology, Duke University, Box 3433, Durham,
NC 27710.
Address reprint requests to: R. Schulte-Hermann, Institute fur
Tumorbiologie-Krebsforschung, A-1090 Wien, Borschkegasse 8a,
Austria.
This paper was presented at the Symposium on Cell Proliferation
and Chemical Carcinogenesis that was held January 14-16, 1992, in
Research Triangle Park, NC.
cytochromes P450, ofother drug-metabolizing enzymes,
or ofenzymes involved in fatty acid metabolism (1,3,4).
Typically, these agents induce an initial burst of
enhanced cell proliferation, which disappears after a
few days, despite further treatment. This burst results
in the development of hyperplasia, which usually is
sustained as long as treatment lasts. In fact, as in other
systems where nongenotoxic carcinogens or tumor
promoters have been studied, sustained hyperplasia
seems to be a common denominator.
When treatment is stopped, a rapid regression of
hyperplasia may occur, depending on the compound.
This regression in the liver is due to a steep increase
in the rate of apoptosis. (5). Apoptosis is a process
whereby organisms can actively eliminate excessive
or damaged cells (6). In the liver and other organs,
apoptosis is complementary to mitosis, maintaining
adequate cell numbers. Apoptosis was originally
defined by Kerr et al. on morphological and functional
grounds (6). Up to now, morphological characteristics
(particularly when light and electron microscopy areSCHULTE-HERMANETAL
Table 1. Inhibition ofapoptosis by tissue-specific
mitogens.
Tissue Mitogen Reference
Adrenal cortex ACTH (6)
Liver CPA, PB, cx-HCH, Naf (7)
Liver preneoplasia PB, CPA (7)
Prostate Testosterone (25)
Neuronal cells NGF (26)
Thymocytes TPA (27)
Estrogen-dependent DES (17)
Kidney tumor
Abbreviations: ACTH, adrenocorticotrophic hormone; CPA,
cyproterone acetate; PB, phenobarbital; HCH, hexachlorocyclohexa-
ne; NGF, nerve growth factor; TPA, 12-0-tetradecanoylphorbol-13-
acetate; DES, diethylstilbestrol.
combined) and functional criteria are the most reliable
markers ofapoptosis.
Among the functional characteristics, inhibition of
apoptosis by tissue-specific growth factors and mito-
gens is of great interest (Table 1). Inhibition may be
used to discriminate apoptosis from necrosis (5-7) and
supports the regulatory role of apoptosis in tissue
homeostasis.
Apoptosis has generally been assumed to be a rapid
process; recently a direct estimation in the liver
revealed that the duration of the histologically visible
stages in this organ is approximately 3 hr (8).
Apoptosis does not appear to occur at random in all
hepatocytes. During regression of mitogen-induced
hyperplasia, nonproliferating (old) hepatocytes seemed
to be preferred for apoptosis. Furthermore, studies on
apoptosis in putative preneoplastic foci of rat liver
have shown that foci cells exhibit about 10-fold higher
rates ofapoptosis than normal hepatocytes (7,12). The
cellular and molecular basis ofthis apparent selectivity
ofapoptotic mechanisms is not known.
Role of Cell Replication and
Apoptosis in Multistep Chemical
Carcinogenesis
It is generally accepted that cell proliferation plays
an important role at different stages ofcancer develop-
ment. Duringinitiation, cell replication is considered to
"fix" genetic insults. Promotion includes amplification
ofinitiated cells and therefore by definition depends on
cell proliferation. Multiple studies supporting the
importance of cell proliferation have been published
and reviewed (1,9-12); they will not be discussed here.
Apoptosis may also have important roles in different
stages ofcarcinogenesis. We described some years ago
that putative preneoplastic liver cells not only show
higher replicative activity than normal liver cells but
also enhanced rates of apoptosis which may balance
proliferation so that no net growth results (7,12).
Recently, Moolgavkar et al. (13), on the basis ofmathe-
matical calculations offocigrowth rates, predicted that
initiated cells can be extinguished. Columbano et al.
(14) provided the first experimental evidence support-
ing this prediction. They showed that initiating doses
of various genotoxins do not produce stable initiation
in a hyperplastic liver undergoing massive regression
through apoptosis.
We recently tried to quantify initiated cells in the
early stages ofcancer development, namely in the first
days after the cytotoxic dose of the initiating carcino-
gen N-nitrosomorpholine (NNM). Glutathione-S-trans-
ferase (GST-P) was used as a marker as described by
Ito (15). Coinciding with regenerative DNA synthesis,
there was a dramatic increase ofGST-P positive single
cells and mini-foci, which after a plateau declined and
finally reached approximately 20% of the peak value.
Although there is no absolute proof that GST-P posi-
tive cells are truly initiated and that they only disap-
pear through apoptosis, these observations fit well the
mathematical predictions (13). A similar decline of
GST-P positive cells has also been observed by Satoh
et al. (16) in a study with diethylnitrosamine. Thus, it
seems likely that initiated cells can be eliminated
under certain experimental conditions, and the old
dogma that initiation is irreversible may need some
modification in the future.
When investigating the promotion stage after NNM
treatment, we noted two apparent paradoxes. The first
one was that putative preneoplastic foci exhibited
much higher cell proliferation than normal liver but
showed almost no net growth. We then found high
apoptotic activity in foci, which apparently balanced
enhanced cell replication (7). The second paradox was
that during tumor promotion by phenobarbital (PB), a
rapid expansion ofphenotypically altered foci occurred
without a persistent increase of cell proliferation. The
explanation was that PB (and other tumor promoters)
can inhibit apoptosis in foci (7). The enhanced apoptotic
activity was associated with an apparent phenotypic
instability ofthe foci, which may reflectthe situation in
the normal tissue where apoptosis occurs during down
regulation ofthe pleiotropic response (12).
Apoptosis also occurs in later stages of carcinoma
development, namely, in neoplastic nodules and malig-
nant tumors (6). Some observations have shown that
tumor cells may depend on the presence oftrophic hor-
mones (17,18). Using an estrogen-dependent trans-
plantable hamster kidney tumor, we recently observed
that withdrawal of diethylstilbestrol (DES) enhanced
apoptosis and decreased mitosis, whereas treatment
with DES had the opposite effects on both events (17).
It appears therefore that both cell replication and cell
death by apoptosis are regulated in concert to produce
regression or growth of organs and that these basic
mechanisms are still functioning in malignant tumors,
although they are obviously out ofbalance. Chemicals
may shift the delicate balance between replication and
death of cells (Fig. 1). The roles of apoptosis in the
stages ofcarcinogenesis are summarized in Table 2.
In conclusion, for understanding chemically induced
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FIGURE 1. Regulation ofgrowth and involution oftissues.
Table 2. Importance ofapoptosis in the stepwise
development ofcancer.
Initiation Efficiency determined by death/disap-
pearance ofinitiated cells. Can initia-
tion be reversible?
Promotion Clonal expansion favored by inhibi-
tion ofapoptosis by tumorpromoter.
Reversibility ofpromotion by
enhanced apoptosis after promoter
withdrawal.
Tumor growth Rate determined by balance between
cell replication and cell death.
Apoptosis can be increased by with-
drawal oftrophic hormones or by
treatment with antihormones.
carcinogenesis and for evaluating health risks, studies
restricted to single phenomena such as mutagenesis,
mitogenesis, cell death, or others are not sufficient. It
is essential that all factors are taken into account and
that an attempt is made to understand the complex
interplay of chemicals and processes at the various
stages of carcinogenesis. It should also be pointed out
in this context that the term mitogen can be highly
misleading when its possibly inherent potential to
inhibit cell death is not taken into account. We there-
fore recommend restriction ofthe term mitogen to sit-
uations where mitotic events are addressed and use of
the term growth stimulus in less specific situations.
TGF-f, As a Signal Regulating
Apoptosis
Obviously, understanding the regulation ofinitiation
ofapoptosis is important for elucidating mechanisms of
chemical carcinogenesis. As a first candidate, we
selected transforming growth factor TGF-P,, which is
associated with negative growth control in the liver
and in some other epithelial tissues (19). Furthermore,
some peptides related to TGF-P, such as anti-
Mullerian hormone have already been shown to induce
regression oftissues.
We found that cells undergoing apoptosis in the liver
in vivo show immunostaining with antibodies against
an epitope ofthe precursor molecule ofTGF-P1, where-
as normal or necrotic hepatocytes were not stained
(20). Furthermore, there were a few isolated, intact
hepatocytes that reacted with the antibodies, and their
incidence correlated with the incidence of apoptosis in
the liver. These cells were smaller, suggesting conden-
sation of the cytoplasm, an early feature of apoptosis.
These findings suggest that hepatocytes preparing for
apoptosis may either synthesize TGF-P1 or take it up
selectively from neighboring cells in its precursor
form. In any event, the precursor of TGF-P1 or its
breakdown products persist in the cytoplasm beyond
the point where protein synthesis and intercellular
exchange cease in apoptotic hepatocytes (20).
To test whether TGF-P1 would actually be able to
induce apoptosis, we added it to cultures of isolated
hepatocytes or injected it in vivo. In both situations, a
striking increase of apoptosis could clearly be demon-
strated. Furthermore, it was found that a putative pre-
cursor of TGF-.i1, the latency-associated peptide
(obtained from Dr. A. Purchio, Seattle, WA) was less
active to induce apoptosis (20,22). This suggests that
TGF-,B1 in its mature form is a trigger for apoptosis in
hepatocytes.
Cell death by apoptosis is frequently associated with
endonuclease activation and formation ofa characteris-
tic DNA fragment pattern (DNA ladder) resulting
from oligonucleosomes (23). This has led some authors
to hypothesize that endonuclease activation is an early
and necessary step of apoptosis. In contrast, we have
not been able to demonstrate endonuclease activation
early during apoptosis in TGF-f1-treated hepatocytes
(24). Therefore, the characteristic DNA fragmentation
(ladder formation) does not appear to be aphenomenon
generally occurring during apoptosis, at least not as
one ofthe initial steps. Ladder formation should not be
used as the sole marker ofapoptosis.
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